CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.53 billion. The enterprise value is $2.33 billion.
| Market Cap | 1.53B |
| Enterprise Value | 2.33B |
Important Dates
The last earnings date was Wednesday, July 29, 2026, after market close.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
CONMED has 29.95 million shares outstanding. The number of shares has decreased by -1.22% in one year.
| Current Share Class | 29.95M |
| Shares Outstanding | 29.95M |
| Shares Change (YoY) | -1.22% |
| Shares Change (QoQ) | -1.65% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 115.22% |
| Float | 29.66M |
Valuation Ratios
The trailing PE ratio is 27.74 and the forward PE ratio is 11.39. CONMED's PEG ratio is 2.36.
| PE Ratio | 27.74 |
| Forward PE | 11.39 |
| PS Ratio | 1.12 |
| Forward PS | 1.09 |
| PB Ratio | 1.47 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.38 |
| P/OCF Ratio | 10.16 |
| PEG Ratio | 2.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.23, with an EV/FCF ratio of 17.30.
| EV / Earnings | 41.18 |
| EV / Sales | 1.70 |
| EV / EBITDA | 10.23 |
| EV / EBIT | 15.17 |
| EV / FCF | 17.30 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.80.
| Current Ratio | 1.48 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 3.50 |
| Debt / FCF | 6.20 |
| Interest Coverage | 5.12 |
Financial Efficiency
Return on equity (ROE) is 5.53% and return on invested capital (ROIC) is 5.65%.
| Return on Equity (ROE) | 5.53% |
| Return on Assets (ROA) | 4.14% |
| Return on Invested Capital (ROIC) | 5.65% |
| Return on Capital Employed (ROCE) | 8.31% |
| Weighted Average Cost of Capital (WACC) | 6.80% |
| Revenue Per Employee | $351,707 |
| Profits Per Employee | $14,486 |
| Employee Count | 3,900 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, CONMED has paid $26.73 million in taxes.
| Income Tax | 26.73M |
| Effective Tax Rate | 32.12% |
Stock Price Statistics
The stock price has decreased by -4.47% in the last 52 weeks. The beta is 0.90, so CONMED's price volatility has been lower than the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -4.47% |
| 50-Day Moving Average | 41.78 |
| 200-Day Moving Average | 40.19 |
| Relative Strength Index (RSI) | 66.00 |
| Average Volume (20 Days) | 489,803 |
Short Selling Information
The latest short interest is 846,967, so 2.83% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.83% |
| Short % of Float | 2.86% |
| Short Ratio (days to cover) | 2.92 |
Income Statement
In the last 12 months, CONMED had revenue of $1.37 billion and earned $56.50 million in profits. Earnings per share was $1.84.
| Revenue | 1.37B |
| Gross Profit | 762.31M |
| Operating Income | 153.32M |
| Pretax Income | 83.23M |
| Net Income | 56.50M |
| EBITDA | 227.46M |
| EBIT | 153.32M |
| Earnings Per Share (EPS) | $1.84 |
Balance Sheet
The company has $37.33 million in cash and $834.25 million in debt, with a net cash position of -$796.92 million or -$26.61 per share.
| Cash & Cash Equivalents | 37.33M |
| Total Debt | 834.25M |
| Net Cash | -796.92M |
| Net Cash Per Share | -$26.61 |
| Equity (Book Value) | 1.04B |
| Book Value Per Share | 34.73 |
| Working Capital | 220.27M |
Cash Flow
In the last 12 months, operating cash flow was $150.59 million and capital expenditures -$16.12 million, giving a free cash flow of $134.46 million.
| Operating Cash Flow | 150.59M |
| Capital Expenditures | -16.12M |
| Depreciation & Amortization | 74.14M |
| Net Borrowing | -43.18M |
| Free Cash Flow | 134.46M |
| FCF Per Share | $4.49 |
Margins
Gross margin is 55.58%, with operating and profit margins of 11.18% and 4.12%.
| Gross Margin | 55.58% |
| Operating Margin | 11.18% |
| Pretax Margin | 6.07% |
| Profit Margin | 4.12% |
| EBITDA Margin | 16.58% |
| EBIT Margin | 11.18% |
| FCF Margin | 9.80% |
Dividends & Yields
This stock pays an annual dividend of $0.20, which amounts to a dividend yield of 0.39%.
| Dividend Per Share | $0.20 |
| Dividend Yield | 0.39% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.86% |
| Buyback Yield | 1.22% |
| Shareholder Yield | 1.61% |
| Earnings Yield | 3.69% |
| FCF Yield | 8.79% |
Analyst Forecast
The average price target for CONMED is $45.50, which is -10.91% lower than the current price. The consensus rating is "Hold".
| Price Target | $45.50 |
| Price Target Difference | -10.91% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 3.21% |
| EPS Growth Forecast (3Y) | 5.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 1.94 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.94 |
| Piotroski F-Score | 6 |